Genetic alterations in primary and secondary hyperparathyroidism

Pathology International

Volumn 48, Issue 8, 1998, Pages 569-574

  Shan, Liang ^a   Nakamura, Yasushi ^a   Nakamura, Misa ^a   Yokoi, Toyoharu ^a   Kakudo, Kennichi ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Genetics; Parathyroid; Primary hyperparathyroidism; Secondary hyperparathyroidism

Indexed keywords

CHROMOSOME 1Q; GENE LOCUS; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HYPERCALCEMIA; HYPOCALCIURIA; JAW TUMOR; ONCOGENE RET; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; REVIEW; SECONDARY HYPERPARATHYROIDISM;

EID: 0031661755     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.1998.tb03952.x     Document Type: Review

References (55)

1. Arnold A, Brown MF, Urea P et al. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J. Clin. Invest. 1995; 95: 2047-2053.
2. Grimelius L, Johansson H. Parathyroid histopathology. Endocr. Pathol. 1996; 7: 165-171.
3. Tahara H, Arnold A. Molecular basis of hyperparathyroidism. J. Bone Miner. Metab. 1997; 15: 173-178.
4. Calender A, Cougard P. Primary hyperparathyroidism: Genetic heterogeneity suggesting different pathogenesis in sporadic and familial forms of parathyroid hyperplasia and tumors. Eur. J. Endocrinol. 1996; 134: 263-266.
5. Farnebo F, Teh BT, Dotzenrath C et al. Differential loss of heterozygosity in familial, sporadic and uremic hyperparathyroidism. Hum. Genet. 1997; 99: 342-349.
6. Fialkow PJ, Jackson CE, Block MA et al. Multicellular origin of parathyroid adenomas. N. Engl. J. Med. 1977; 297: 696-698.
7. Arnold A, Staunton CE, Kim HG et al. Monoclonality and abnormal parathyroid hormone genes in parathyroid adenomas. N. Engl. J. Med. 1988; 318: 658-662.
8. Shan L, Nakamura M, Nakamura Y et al. Comparative analysis of clonality and pathology in primary and secondary hyperparathyroidism. Virchows Arch. 1997; 430: 247-251.
9. Lubensky IA, Debelenko LV, Zhuang Z et al. Allelic deletions on chromosome 11q13 in multiple tumors from individual MEN 1 patients. Cancer Res. 1996; 56: 5272-5278.
10. Friedman E, Sakaguchi K, Bale AE et al. Clonality of parathyroid tumors in familial multiple endocrine neoplasia type 1. N. Engl. J. Med. 1989; 321: 213-218.
11. Noguchi S, Motomura K, Inaji H, Imaoka S, Koyama H. Clonal analysis of parathyroid adenomas by means of the polymerase chain reaction. Cancer Lett. 1994; 78: 93-97.
12. Tominaga Y, Kohara S, Namii Y. Clonal analysis of nodular parathyroid hyperplasia in renal hyperparathyroidism. World J. Surg. 1996; 20: 744-752.
13. Shan L, Kakudo K, Nakamura M et al. Clonality of the parathyroid nodules with uremic parathyroid hyperplasia. Pathol. Oncol. Res. 1997; 3: 198-203.
14. Fialkow PJ. Clonal origin of human tumors. Biochim. Biophys. Acta 1976; 458: 283-321.
15. Apel RL, Ezzat S, Bapat BV et al. Clonality of thyroid nodules in sporadic goiter. Diagn. Mol. Pathol. 1995; 4: 113-121.
16. Aeschimann S, Kopp PA, Kimura ED et al. Morphological and functional polymorphism within clonal thyroid nodules. J. Clin. Endocrinol. Metab. 1993; 77: 846-851.
17. Falchetti A, Bale AE, Amorosi A et al. Progression of uremic hyperparathyroidism involves allelic loss on chromosome 11. J. Clin. Endocrinol. Metab. 1993; 76: 139-144.
18. Brandi ML. Parathyroid tumor biology in familial multiple endocrine neoplasia type 1: A model for cancer development. Henry Ford Hosp. Med. J. 1992; 40: 181-185.
19. Jimbo H, Hitomi Y, Yoshikawa H et al. Evidence for monoclonal expansion of epithelial cells in ovarian endometrial cysts. Am. J. Pathol. 1997; 150: 1173-1178.
20. Dijkhuizen SM, Entius MM, Clement MJ et al. Multiple hyperplastic polyps in the stomach: Evidence for clonality and neoplastic potential. Gastroenterology 1997; 112: 561-566.
21. Larsson C, Skogseid B; Öberg K et al. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988; 332: 85-87.
22. Chandrasekharappa SC, Gurum SC, Manickam P et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997; 276: 404-407.
23. The European Consortium on MEN 1. Identification of the multiple endocrine neoplasia type 1 (MEN 1) gene. Hum. Mol. Genet. 1997; 6: 1177-1183.
24. Agarwal SK, Kester MB, Debelenko LV et al. Germline mutations of the MEN 1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum. Mol. Genet. 1997; 6: 1169-1175.
25. Shimizu S, Tsukada T, Futami H et al. Germline mutations of MEN 1 gene in Japanese kindred with multiple endocrine neoplasia type 1. Jpn. J. Cancer Res. 1997; 88: 1029-1032.
26. Tahara H, Smith AP, Gas RD, Cryns VL, Arnold A. Genomic localization of novel candidate tumor suppressor gene loci in human parathyroid adenomas. Cancer Res. 1996; 56: 599-605.
27. Heppner C, Kester MB, Agarwal SK et al. Somatic mutation of the MEN 1 gene in parathyroid tumors. Nature Genet. 1997; 16: 375-378.
28. Friedman E, DeMarco L, Gejman PV et al. Allelic loss from chromosome 11 in parathyroid tumors. Cancer Res. 1992; 52: 6804-6809.
29. Shan L, Nakamura Y, Nakamura M et al. Somatic mutations of MEN 1 gene in the sporadic endocrine tumors. Lab. Invest. 1998 (in press).
30. Friedman E, Bale AE, Marx SJ et al. Genetic abnormalities in sporadic parathyroid adenomas. J. Clin. Endocrinol. Metab. 1990; 71: 293-297.
31. Hosokawa Y, Tu T, Tahara H, Smith AP, Arnold A. Absence of cyclin D1/PRAD 1 point mutations in human breast cancers and parathyroid adenomas and identification of a new cyclin D1 gene polymorphism. Cancer Lett. 1995; 93: 165-170.
32. Hsi ED, Zukerberg LR, Yang WI et al. Cyclin D1/PRAD1 expression in parathyroid adenomas: An immunohistochemical study. J. Clin. Endocrinol. Metab. 1996; 81: 1736-1739.
33. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 Mutations in human cancer. Science 1991; 253: 49-53.
34. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991; 351: 453-456.
35. Dotzenrath C, Teh BT, Farnebo F et al. Allelic loss of the retinoblastoma tumor suppressor gene: A marker for aggressive parathyroid tumors? J. Clin. Endocrinol. Metab. 1996; 81: 3194-3196.
36. Cryns VL, Thor AD, Xu H-J et al. Loss of the retinoblastoma tumor suppressor gene in parathyroid carcinoma. N. Engl. J. Med. 1994; 330: 757-761.
37. Cryns VL, Rubio M-P, Thor AD et al. p53 Abnormalities in human parathyroid carcinoma. J. Clin. Endocrinol. Metab. 1994; 78: 1320-1324.
38. Subramaniam P, Wilkinson S, Shepherd JJ. p53 Tumor suppressor gene expression in hyperparathyroidism. Aust. N. Z. J. Surg. 1996; 66: 302-304.
39. Yoshimoto K, Iwahana H, Fukuda A et al. Role of p53 mutations in endocrine tumorigenesis: Mutation detection by polymerase chain reaction-single strand conformation polymorphism. Cancer Res. 1992; 52: 5061-5064.
40. Bondeson L, Sandelin K, Grimelius L. Histopathological variables and DNA cytometry in parathyroid carcinoma. Am. J. Surg. Pathol. 1993; 17: 820-829.
41. Takahashi M, Buma Y, Iwamoto T et al. Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 1988; 3: 571-578.
42. Lioyd RV. RET proto-oncogene mutations and rearrangements in endocrine diseases. Am. J. Pathol. 1995; 147: 1539-1544.
43. Padberg B-C, Schroder S, Jochum W et al. Absence of ret proto-oncogene point mutations in sporadic hyperplastic and neoplastic lesions of the parathyroid gland. Am. J. Pathol. 1995; 147: 1600-1607.
44. Williams GH, Rooney S, Carss A, Cummins G, Thomas GA, Williams ED. Analysis of the RET proto-oncogene in sporadic parathyroid adenomas. J. Pathol. 1996; 180: 138-141.
45. Kimura T, Yoshimoto K, Tanaka C et al. Obvious mRNA and protein expression but absence of mutations of the ret proto-oncogene in parathyroid tumors. Eur. J. Endocrinol. 1996; 134: 314-319.
46. Pollak MR, Brown EM, Chou Y-HW et al. Mutations in the human calcium-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 1993; 75: 1297-1303.
47. Thompson DB, Samowitz WS, Odelberg S et al. Genetic abnormalities in sporadic parathyroid adenomas: Loss of heterozygosity for chromosome 3q markers flanking the calcium receptor locus. J. Clin. Endocrinol. Metab. 1995; 80: 3377-3380.
48. +-sensing receptor gene in human parathyroid tumors. J. Clin. Endocrinol. Metab. 1995; 80: 3107-3110.
49. Szabó J, Heath B, Hill VM et al. Hereditary hyperparathyroidism-jaw tumor syndrome: The endocrine tumor gene HRPT2 maps to chromosome 1q21-q23. Am. J. Hum. Genet. 1995; 56: 944-950.
50. Teh BT, Farnebo F, Kristoffersson U et al. Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney diseases: Linkage to 1q21-q32 and loss of the wild type allele in renal hamartomas. J. Clin. Endocrinol. Metab. 1996; 81: 4204-4211.
51. Cryns VL, Yi, SM, Tahara H et al. Frequent loss of chromosome arm 1p DNA in parathyroid adenomas. Genes Chromosomes Cancer 1995; 13: 9-17.
52. Williamson EA, Johnson SJ, Foster S, Kendall-Taylor P, Harris PE. G protein gene mutations in patients with multiple endocrinopathies. J. Clin. Endocrinol. Metab. 1995; 80: 1702-1705.
53. Yoshimoto K, Iwahana H, Fukuda A, Sano T, Itakura M. Rare mutations of the Gs alpha subunit gene in human endocrine tumors. Cancer 1993; 72: 1386-1393.
54. Vessey SJ, Jones PM, Wallis SC, Schofield J, Bloom SR. Absence of mutations in the Gs alpha and Gi2 alpha genes in sporadic parathyroid adenomas and insulinomas. Clin. Sci. (Colch.) 1994; 87: 493-497.
55. Tahara H, Smith AP, Gaz RD et al. Loss of chromosome arm 9p DNA and analysis of the p16 and p15 cyclin-dependent kinase inhibitor genes in human parathyroid adenomas. J. Clin. Endocrinol. Metab. 1996; 81: 3663-3667.